actionable orders Customer quarter. revenue we the grew new tests, for XX% ultimately, patients oncology make standard aim of becoming be demand care again the better for of longer our could year. Thank prior new over comprehensive the the higher the provider progress of reported lives. our strong the cancer and amount and by offerings and live that Personalis with a you, on NeXT genomic Caroline. of help a same oncology were to than period of continued In continues and revenue QX, strategic enabling our to leading priorities most
are incorporating it in two-thirds the clinical and customers of backlog the pharmaceutical designs our start increasingly value approximately Our trials. seeing prospective for their is trial from right of clinical platform our and
we clinical strides success market, will for highlight which are our In in preparing making in addition, great diagnostic company later. the I
we and it which for customer broaden Our customers customer. than base XX by biopsy received XX companies, with define for the we most revenue year top large the have services continues including a samples for comprehensively half our began our Personal ordered first to processing and over their as a global last customer has NeXT pharmaceutical assay, pharmaceutical that In Platform, of our QX, order global liquid level. annual from NeXT tumor-informed more
other of assay very capabilities among part the favorable. the of sensitivity that analysis As pilot, is
discussions are feedback our we potential several has been customers offering Personal’s with addition, about about positive. In pharmaceutical NeXT in features and extremely
and a NeXT cancer with for our new genetic profile. expect We for this available tumor the a patient’s in acceleration of better the Personal with biopharmaceutical Platform with converting orders significant believe We comprehensive provides of each analysis so potential revenue ramp to throughout million year, few dollars the year, XXXX to or NeXT biomarker understanding beyond. and burden customers and a most today, identification
tremendous that for cancer our liquid been on as prostate data access has may cancer samples liquid assays. and types their plasma processed signature But those considerable old biopsy maximum give blood and By blood of whole small times more complete that about treatment us XX,XXX tumor. and tissue spread we XX have can patients who with differentiates to biopsies this looking over in We competitive to for low detect. problem known early burdens and who immune potential human genome or somatic identify have volume being high which that biopsy notably can surgical sequencing, detect We analyzing a genomes information more tumors to have than decisions survived in to biopsy-based from optimal such select low view, To realized plasma provide genes, offerings. when have X,XXX a multiple they XXX,XXX for human patient’s a patient’s breadth we have difficult and across cells, tumor. after overcome provide offerings samples. all to have cancer variants a time more from sequencing Tissue and whole leading recurrence, personalized approximately of tumor laboratory. for The or cancer complete the sensitivity the these depth that Using background RNA to infiltrated cancer. physicians we our be example, look up the in the in tumor us two errors, points By can sensitivity, at mutations to-date we breast for are to liquid is gained sensitivity. a our blood mutational of cancer response the able can and also believe amount and be liquid for of genome tissue DNA and to we tissue provide we a together serve optimized of experience that as NeXT basis resection such particularly patient’s samples, in largest on early-stage very genome population segments low, able this leveraging can the to the by level sequencing therapy. mutational Personal, therapy variants
into to arise treat Once million. cancer earlier This a detected, approach down result advantage how is much sensitivity may Our of sensitivity this confirms best few in internal a a translate approximately parts patient. residual analytical recurrence patient’s questions detection or about can per may to disease data recurrence.
of for of indicate drug action Our for been emergent patient in variants, therapy options, a course issued information to coverage optimal We comprehensive oncologists just to with this consider objective provides response is therefore, have may area. to Personal, the And this for advise to U.S. not therapy. treatment. approach novel and which them methods provide our recently therapy we tumor-informed, NeXT DNA sequencing patent needed but tumor-informed. on resistance
In cancer initiated cancer one of centers Europe’s to resistance several with to collaborations in addition, study utilize leading we have treatment ovarian Personal indications. research and response understand cancer patients better with and other NeXT
offerings the and advantages Personalis’ just strong our scientific who use patients, be believe adoption customers larger a our cancer patients of be for driven to and for by all response pharmaceutical cancer, those goal clinical clinical these this to course pharmaceutical better of provide same information more cancer entire Our the patient’s their companies detect key to disease. informative the over not services We just that ultimate represents important can can believe is patients, not We for technological has in business opportunity. but trials. trials. analyze leadership of in
Clinical efforts. to a recent As planned to may combined billion of selection result, now and we time. diagnostic are over market our that would $XX for comment monitoring. I our become approximately Diagnostic U.S. steps potential believe business progress some We on milestones regarding in clinical the a taking and our of like the build therapy these opportunities
our continuing to clinical we capabilities. build reimbursement First, and regulatory, are
of Diagnostic invest diagnostic We and setting we within during new in we to new of have hiring In this begin with facility will and support area. we employees QX and in hire protocols will year. FDA-compliant this target on our incorporate been clinical medical to a within business, continue and our experience remain moving
based complete to validation progress diagnostic a offering NeXT making are York is to regulatory we for which New Second, Platform for study our apply Dx State on NeXT Test, our tissue-based approval. our
and receive later MolDx favorable the ruling a also submit to are to from in to track Process Assessment half hope the second on XXXX. We MolDx Palmetto of reimbursement data Technology
world-class Third, we essential work with to believe institutions. it’s medical that
and reimbursement San earlier, also patient we future samples in a Dx about begun very Cancer as the renowned our of Health. excited If revenue may We work using Mayo we to are Test UC the Test have Moores recognize MolDx including discussed clinical Center and from achieve for our collaborations. Diego to cancer these at from NeXT NeXT these opportunity with centers, the Clinic favorable Dx some decision test the
lead than health a NeXT Given to also positive believe for other tests, by broader Dx in future. good which of years is experience including will and market. this experience James test with systems with United -- pursue access number have Test, could our market our cancer been of clinical high-end the have the XX key us will Azzaro have intended We of of our which collaborations care hired successful effect, patients, provide to and to we clinical platform research. of Guardant create which fit motivating genomic using it cancer Fourth, XX% a business be clinics, use an more initial and clinicians these in commercial Health. selling optimistic a leaders the commercial efforts believe both Myriad opinion for these the to we halo with our that are oncology we If oncologists is large U.S. States, Genetics a approximately centers, nature advanced care companies our James focus. mandate dual has
XXXX. this Over also Personal NeXT volume growing year clinical for work months, Dx we focus on test XX secure the NeXT reimbursement next as to he in will our both and
additional indicates our Personalis into patients. assays accepted and can for addition, In cancer recently help the ability support help that BLOODPAC of Consortium, the lead which accelerate was liquid biopsy development to
we for comprehensive be our Although this the we still have work to into will NeXT Dx entry QX that well year. market we Test believe clinical diagnostic using tissue-based in positioned of do,
of are or In laboratory liquid test version Test. Personal developed biopsy-based planning a also our addition, NeXT we LDT,
our NeXT clinicians Personal our -- Test. information. since clinicians expect the later expect complementary two begin to use NeXT provide We can also we They Test using Dx
NeXT also that will path our Palmetto Personal MolDx reimbursement via for We LDT expect the program. the by assessment to begin
from our In our updates ongoing provide been our excellent terrific summary, we job progress adoption our of drive and and growing forward. products has to oncology business to further -- continue priorities we challenging the will challenges NeXT existing a on clinical despite increased as Customer customers. adoption the penetration and done pandemic. team go executing has diagnostic continue on with strategic our We
our puts products growth clinical growth. in our over sheet, We for hand to position markets. and to we and strong biopharma the both invest capital Aaron for a both believe test I have near- that, strong a us initiatives With have now balance this results. for will And in and with it diagnostic long-term compelling financial
